文献速递前列腺癌

多参数磁共振成像作为前列腺癌高临床疑似男性一线工具的临床效用

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

基于1140例前列腺特异性抗原>4ng/ml男性的随机单中心研究数据,比较初始经直肠超声引导活检(TRUS-Bx)与3-T多参数磁共振引导活检(mpMRI-Bx)路径的诊断与治疗成本及效果。mpMRI-Bx路径诊断成本高14.6%、治疗成本高5.2-6.0%,但排除临床显著疾病(Gleason≥7)的敏感度和阴性预测值均为100%(95%CI 98-100%),且诊断时间显著更短(中位4.0个月 vs 6个月,p<0.001)。

要点

  • mpMRI-Bx路径诊断成本较TRUS-Bx高14.6%,治疗成本高5.2-6.0%。
  • mpMRI-Bx排除Gleason≥7疾病的敏感度和阴性预测值均为100%(95%CI 98-100%)。
  • mpMRI-Bx诊断时间中位4.0个月,显著短于TRUS-Bx的6个月(p<0.001)。

核心结论

  • mpMRI-Bx策略对临床疑似前列腺癌患者的诊断有效,提供更准确的诊断,联合诊断与治疗成本仅较标准策略适度增高。

研究设计与样本

  • 利用随机单中心研究数据对1140例前列腺特异性抗原>4ng/ml患者进行成本与时间分析,其中570例接受初始TRUS-Bx,570例接受3-T mpMRI-Bx。
  • 采用意大利国家卫生安全系统报销数据进行预算分析,分别分析可报销的诊断与治疗成本,并比较组织学结局、路径诊断准确性、治疗选择及诊断时间。

主要发现

  • mpMRI-Bx路径累计诊断成本较TRUS策略高14.6%,治疗成本高5.2-6.0%。
  • 诊断成本mpMRI-Bx为228 946欧元,TRUS-Bx为199 750欧元;治疗成本分别为1 912 000欧元和1 802 800欧元。
  • mpMRI-Bx策略排除临床显著疾病(Gleason≥7)的敏感度和阴性预测值均为100%(95%CI 98-100%)。
  • 诊断时间mpMRI-Bx中位4.0个月(四分位距3-6),TRUS-Bx中位6个月(四分位距4-12),mpMRI-Bx显著更短(p<0.001)。

临床怎么用

  • 原文结论认为mpMRI-Bx策略对临床疑似前列腺癌患者诊断有效,提供更准确诊断,联合诊断与治疗成本仅适度增高。

局限性

  • 缺乏治疗相关并发症的成本数据。
  • 缺乏随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transrectal ultrasound-guided biopsy (TRUS-Bx) is recommended by the European Urology Association (EAU) as the first diagnostic modality for men at risk of prostate cancer (PCa). Current EAU guidelines reserve the use of multiparametric MRI to target or guide any repeat biopsy (mpMRI-Bx). It remains uncertain if TRUS-Bx is effective as a first strategy in terms of costs, diagnostic performance, time to diagnosis, and triage for individualised therapy. OBJECTIVE: To determine the diagnostic and treatment costs and the effectiveness of pathways incorporating mpMRI-Bx compared to TRUS-Bx in men at high risk of PCa. DESIGN, SETTING, AND PARTICIPANTS: A cost and time analysis was performed using data from a randomised single-centre study of 1140 patients (prostate-specific antigen >4ng/ml) divided into two groups: 570 patients underwent an initial TRUS-Bx and 570 underwent 3-T mpMRI-Bx. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Budget analyses were used to compare the diagnostic strategies using reimbursement data from the Italian National Health Security system. Analyses of reimbursable diagnostic and treatment costs were undertaken separately. Histologic outcomes, pathway diagnostic accuracy, therapy choices, and time to diagnosis were compared. RESULTS AND LIMITATIONS: The cumulative diagnosis costs were 14.6% greater for the mpMRI-Bx pathway than for the TRUS strategy, and 5.2-6.0% higher for therapy. Diagnostic costs were €228 946 for mpMRI-Bx and €199 750 for TRUS-Bx, and the corresponding therapy costs were €1 912 000 and €1 802 800. The mpMRI-Bx strategy was highly effective in excluding clinically significant disease (Gleason ≥7; sensitivity and negative predictive value both 100%, 95% confidence interval 98-100%). The time to diagnosis was significantly shorter for the mpMRI-Bx (median 4.0 mo interquartile range [IQR] 3-6) than for the TRUS-Bx strategy (median 6 mo, IQR 4-12; p<0.001). Limitations include the lack of data on costs associated with treatment-related complications and follow-up data. CONCLUSIONS: The mpMRI-Bx strategy is effective for diagnosing patients with a clinical suspicion of PCa and provides more accurate diagnosis, with combined diagnosis and therapy costs only moderately higher than for the standard strategy. PATIENT SUMMARY: It is a matter of debate whether a diagnostic pathway that incorporates multiparametric magnetic resonance imaging (MRI) as the first-line test before performing any type of biopsy in men suspected of having prostate cancer (PCa) is cost-effective. Our analysis of the costs for men suspected of harbouring PCa revealed higher diagnostic costs for the MRI approach, with the benefits of greater diagnostic accuracy. Moreover, the combined diagnostic and treatment costs are only modestly higher whenever the same treatment for all patients is considered.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Panebianco V, Valerio MC, Giuliani A, et al. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31102623. doi:10.1016/j.euo.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。